Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14683599 | 0.96 | GLP1R (0.44) | GLP1RFAAHTSHRRECQLMEN1 | |
| SCHEMBL14683514 | 0.93 | GLP1R (0.46) | GLP1RFAAHTSHRRECQLMEN1 | |
| SCHEMBL14725960 | 0.93 | GLP1R (0.46) | GLP1RFAAHTSHRRECQLMEN1 | |
| SCHEMBL14683597 | 0.91 | GLP1R (0.43) | GLP1RFAAHMEN1KMT2ATLR2 | |
| SCHEMBL29330865 | 0.88 | GLP1R (0.57) | GLP1RFAAHTSHRRECQLTLR2 | |
| SCHEMBL14685801 | 0.87 | GLP1R (0.48) | GLP1RFAAHTSHRRECQLMEN1 | |
| SCHEMBL15259289 | 0.85 | GLP1R (0.46) | GLP1RFAAHTSHRRECQLMEN1 | |
| SCHEMBL14998226 | 0.81 | GLP1R (0.60) | GLP1R | |
| SCHEMBL14685781 | 0.81 | GLP1R (0.54) | GLP1RTSHRRECQLTLR2EPHX2 | |
| SCHEMBL14685783 | 0.81 | GLP1R (0.54) | GLP1RFAAHTSHRRECQLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035285-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035285-A1 | NOVEL GLUCAGON ANALOGUES | GLP1R, GIPR, IAPP | GLP1R 1/4885FAAH 1269/4885TSHR 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.